Novo Nordisk's hemophilia drug will be tough competition for Roche's, says Citi
Novo Nordisk’s potential new bleeding medicine Mim8 has a highly competitive profile for the treatment of hemophilia A compared to Roche’s best-selling bleeding medicine, Hemlibra, according to the US bank Citi.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk reaches endpoints in hemophilia medicine trial
For subscribers
Novo Nordisk Foundation: Bernie Sanders is wrong
For subscribers